GlaxoSmithKline News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.06.24	US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk (Businesswire)
07.06.24	US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
06.06.24	GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies (EN, GlaxoSmithKline)
03.06.24	Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer (EN, GlaxoSmithKline)
02.06.24	Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
01.06.24	Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling (EN, GlaxoSmithKline)
23.05.24	Statement: Zantac (ranitidine) litigation - Valadez and Williams cases (EN, GlaxoSmithKline)
21.05.24	GSK announces positive results from phase III severe asthma trials of depemokimab (EN, GlaxoSmithKline)
16.05.24	GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) (EN, GlaxoSmithKline)
01.05.24	GSK makes a strong start to 2024 with improving outlook for the year (EN, GlaxoSmithKline)
17.04.24	EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments (EN, GlaxoSmithKline)
17.04.24	New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade (EN, GlaxoSmithKline)
16.04.24	GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA (EN, GlaxoSmithKline)
16.03.24	Positive RUBY phase III data show potential for Jemperli (dostarlimab) combinations in more patients with primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
07.03.24	GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise (Businesswire)
07.03.24	GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
04.03.24	ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses (EN, GlaxoSmithKline)
29.02.24	GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director (EN, GlaxoSmithKline)
29.02.24	Statement: Zantac (ranitidine) litigation (EN, GlaxoSmithKline)
28.02.24	ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV (EN, GlaxoSmithKline)
26.02.24	GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) (EN, GlaxoSmithKline)
15.02.24	GSK completes acquisition of Aiolos Bio (EN, GlaxoSmithKline)
12.02.24	GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B (EN, GlaxoSmithKline)
06.02.24	GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
06.02.24	GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk (Businesswire)
06.02.24	GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration (EN, GlaxoSmithKline)
05.02.24	DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
01.02.24	Statement: Zantac (ranitidine) litigation (EN, GlaxoSmithKline)
31.01.24	GSK delivers strong 2023 performance and upgrades growth outlooks (EN, GlaxoSmithKline)
29.01.24	GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency for the prevention of RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
29.01.24	European Commission authorises GSK’s Omjjara (momelotinib) (EN, GlaxoSmithKline)
10.01.24	Nucala (mepolizumab) approved in China for use in severe asthma with an eosinophilic phenotype (EN, GlaxoSmithKline)
09.01.24	GSK enters agreement to acquire Aiolos Bio (EN, GlaxoSmithKline)
20.12.23	GSK enters exclusive license agreement with Hansoh for HS-20093 (EN, GlaxoSmithKline)
18.12.23	Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial (EN, GlaxoSmithKline)
12.12.23	GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity (Businesswire)
12.12.23	Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk (EN, GlaxoSmithKline)
11.12.23	GSK’s Jemperli (dostarlimab) plus chemotherapy approved as the first and only frontline immuno-oncology treatment in the European Union for dMMR/MSI-H primary advanced or recurrent endometrial cancer (EN, GlaxoSmithKline)
06.12.23	New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions (EN, GlaxoSmithKline)
30.11.23	New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence (EN, GlaxoSmithKline)
27.11.23	GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma (EN, GlaxoSmithKline)
22.11.23	GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials (EN, GlaxoSmithKline)
13.11.23	GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative (Businesswire)
25.10.23	New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease (Businesswire)
05.09.23	GSK and Earvin "Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations (Businesswire)
17.08.23	GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies (Businesswire)
31.07.23	Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer (Businesswire)
13.07.23	GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US (Businesswire)
21.06.23	GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons (Businesswire)
20.06.23	GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to "Ask2BSure” about Meningitis B (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

27.07.22		GSK-Aktie gefragt: GlaxoSmithKline hebt Jahresziele an
18.07.22		Haleon-Aktie etwas tiefer: GSK-Abspaltung Haleon wird erstmals in London gehandelt
23.06.22		GSK-Aktie in Grün: GSK will Infektionskrankheiten in armen Ländern bekämpfen
06.06.22		GlaxoSmithKline-Aktie stabil: US-Zulassung für Impfstoff Priorix erhalten
01.06.22		GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus
31.05.22		GSK-Aktie legt leicht zu: GlaxoSmithKline erwirbt Biopharma-Spezialisten in Milliardendeal
27.04.22		GSK-Aktie höher: GlaxoSmithKline übertrifft Gewinnerwartungen
27.04.22		Ausblick: GlaxoSmithKline gewährt Anlegern Blick in die Bücher

27.07.22

GSK-Aktie gefragt: GlaxoSmithKline hebt Jahresziele an

18.07.22

Haleon-Aktie etwas tiefer: GSK-Abspaltung Haleon wird erstmals in London gehandelt

23.06.22

GSK-Aktie in Grün: GSK will Infektionskrankheiten in armen Ländern bekämpfen

06.06.22

GlaxoSmithKline-Aktie stabil: US-Zulassung für Impfstoff Priorix erhalten

01.06.22

GSK-Aktie schwach: GlaxoSmithKline will Konsumentensparte Mitte Juli an die Börse bringen - Pfizer steigt aus

31.05.22

GSK-Aktie legt leicht zu: GlaxoSmithKline erwirbt Biopharma-Spezialisten in Milliardendeal